AR126219A1 - TRANSFORMING GROWTH FACTOR b LIGAND TRAPS FOR THE TREATMENT OF DISEASES - Google Patents

TRANSFORMING GROWTH FACTOR b LIGAND TRAPS FOR THE TREATMENT OF DISEASES

Info

Publication number
AR126219A1
AR126219A1 ARP220101657A ARP220101657A AR126219A1 AR 126219 A1 AR126219 A1 AR 126219A1 AR P220101657 A ARP220101657 A AR P220101657A AR P220101657 A ARP220101657 A AR P220101657A AR 126219 A1 AR126219 A1 AR 126219A1
Authority
AR
Argentina
Prior art keywords
growth factor
ligand traps
transforming growth
tgf
diseases
Prior art date
Application number
ARP220101657A
Other languages
Spanish (es)
Inventor
Raymond Fischer Bruce S Hamuro Lora Perez
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR126219A1 publication Critical patent/AR126219A1/en

Links

Abstract

La presente solicitud se refiere a métodos que utilizan trampas de ligandos del factor de crecimiento transformador b (TGF-b). Las trampas de ligandos del TGF-b descritas en el presente documento pueden ser adecuadas para una terapia de combinación con una inmunoterapia, para tratar una enfermedad o trastorno tal como un cáncer. Las trampas de ligandos del TGF-b descritas en el presente documento también pueden ser adecuadas para monoterapia para tratar una enfermedad o trastorno tal como un cáncer. En particular, en el presente documento se proporcionan métodos y composiciones para tratar una enfermedad o trastorno, tal como un cáncer, mediante la administración de una trampa de ligandos del TGF-b en combinación con un inhibidor de puntos de control inmunitario.The present application relates to methods using transforming growth factor b (TGF-b) ligand traps. The TGF-b ligand traps described herein may be suitable for combination therapy with an immunotherapy, to treat a disease or disorder such as cancer. The TGF-b ligand traps described herein may also be suitable for monotherapy to treat a disease or disorder such as cancer. In particular, provided herein are methods and compositions for treating a disease or disorder, such as cancer, by administering a TGF-b ligand trap in combination with an immune checkpoint inhibitor.

ARP220101657A 2020-06-24 2022-06-23 TRANSFORMING GROWTH FACTOR b LIGAND TRAPS FOR THE TREATMENT OF DISEASES AR126219A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063214588P 2020-06-24 2020-06-24
US202163214585P 2021-06-24 2021-06-24

Publications (1)

Publication Number Publication Date
AR126219A1 true AR126219A1 (en) 2023-09-27

Family

ID=88197391

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220101657A AR126219A1 (en) 2020-06-24 2022-06-23 TRANSFORMING GROWTH FACTOR b LIGAND TRAPS FOR THE TREATMENT OF DISEASES

Country Status (1)

Country Link
AR (1) AR126219A1 (en)

Similar Documents

Publication Publication Date Title
MX2020009773A (en) Combination therapy.
CR20170477A (en) FIBROBLAST GROWTH FACTOR RECEIVER COMBINATION THERAPY (FGFR) / SCHEDULED DEATH 1 (PD 1) FOR THE TREATMENT OF THE CNCER
EA202091846A1 (en) COMPOUNDS WITH FERROPTOSIS-INDUCING ACTIVITY AND METHODS OF THEIR APPLICATION
MX2023007212A (en) Epinephrine spray formulations.
AR101740A1 (en) COMBINATION AND COMPOSITION THERAPY
EA201892190A1 (en) TREATMENT OF PSORIASIS WITH ANTI-BODY TO IL-12 AND / OR IL-23 WITH THE GROWTH OF THE INTERVAL BETWEEN THE INTRODUCTION OF DOSE
MX2020001727A (en) Combination therapy.
CO2023017973A2 (en) Transforming Growth Factor βeta Ligand Traps for Disease Treatment
EA202192122A1 (en) COMPOUNDS WITH FERROPTOSE-INDUCING ACTIVITY AND METHODS FOR THEIR APPLICATION
AR119507A1 (en) TRISPECIFIC ANTI-PD-1/LAG3/TIGIT ANTIBODIES AND BISPECIFIC ANTI-PD-1/LAG3 ANTIBODIES
EA202193111A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
CL2019001749A1 (en) Use of anti-sclerostin antibodies in the treatment of imperfect osteogenesis.
MX2019013862A (en) Combination therapy.
BR112022024483A2 (en) METHODS TO TREAT MULTIPLE MYELOMA
MX2022003194A (en) Treatment of behavioral impairment in developmental and epileptic encephalopathy.
CO2022002573A2 (en) Antibodies against ilt2 and their use
EA201891007A1 (en) AIMING FOR FORMILPEPTID RECEPTOR 2 / LIPOXIN A RECEPTOR (FPR2 / ALX) FOR TREATING HEART DISEASES
AR122352A1 (en) A C21-N-PYRAZOLIL 19-NOR C3,3 DISUBSTITUTED STEROID AND METHODS OF USE OF IT
CL2021002966A1 (en) Combination of pd-1 inhibitors and lag-3 inhibitors to improve efficacy in cancer treatment.
BR112022003659A2 (en) Compositions and methods of treatment of vascular diseases
CO2019003865A2 (en) Therapeutic protein
BR112016023011A2 (en) gastric cancer treatment
EA201990613A1 (en) ANTIBODIES AGAINST GREEMLIN-1 (GREM1) AND METHODS OF THEIR APPLICATION FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
MX2020008881A (en) Methods of treatment of cancer comprising chk1 inhibitors.
EA202091112A1 (en) SOCRYSTALS, PHARMACEUTICAL COMPOSITIONS BASED ON THEIR BASED AND METHODS OF TREATMENT FOR THEIR APPLICATION